Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.

Ackerman ME, Dugast AS, Alter G.

Annu Rev Med. 2012;63:113-30. doi: 10.1146/annurev-med-050310-085221. Epub 2011 Nov 8. Review.

PMID:
22077718
2.

HIV-specific antibody immunity mediated through NK cells and monocytes.

Kramski M, Parsons MS, Stratov I, Kent SJ.

Curr HIV Res. 2013 Jul;11(5):388-406. Review.

PMID:
24191935
3.

Systems serology for evaluation of HIV vaccine trials.

Ackerman ME, Barouch DH, Alter G.

Immunol Rev. 2017 Jan;275(1):262-270. doi: 10.1111/imr.12503. Review.

4.

Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies?

Agrati C, D'Offizi G, Gougeon ML, Malkovsky M, Sacchi A, Casetti R, Bordoni V, Cimini E, Martini F.

AIDS Rev. 2011 Jan-Mar;13(1):3-12. Review.

PMID:
21412385
5.

Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Ackerman ME, Alter G.

Curr HIV Res. 2013 Jul;11(5):365-77. Review.

6.

Role of neutralizing antibodies in protective immunity against HIV.

Srivastava IK, Ulmer JB, Barnett SW.

Hum Vaccin. 2005 Mar-Apr;1(2):45-60. Epub 2005 Mar 17. Review.

PMID:
17038830
7.

A brief history of the global effort to develop a preventive HIV vaccine.

Esparza J.

Vaccine. 2013 Aug 2;31(35):3502-18. doi: 10.1016/j.vaccine.2013.05.018. Epub 2013 May 21. Review.

8.

HIV vaccine design: the neutralizing antibody conundrum.

Stamatatos L.

Curr Opin Immunol. 2012 Jun;24(3):316-23. doi: 10.1016/j.coi.2012.04.006. Epub 2012 May 15. Review. No abstract available.

PMID:
22595693
9.

The RV144 Thai HIV vaccine trial.

Plotkin SA.

Hum Vaccin. 2010 Feb;6(2):159. Epub 2010 Feb 18. No abstract available.

PMID:
20431337
10.
11.

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

Koff WC.

Vaccine. 2012 Jun 19;30(29):4310-5. doi: 10.1016/j.vaccine.2011.11.014. Epub 2011 Nov 17. Review.

PMID:
22100891
12.

HIV vaccine development--improving on natural immunity.

Johnston MI, Fauci AS.

N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. No abstract available.

13.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
14.

Non-neutralizing antibodies in prevention of HIV infection.

Robinson HL.

Expert Opin Biol Ther. 2013 Feb;13(2):197-207. doi: 10.1517/14712598.2012.743527. Epub 2012 Nov 6. Review.

PMID:
23130709
15.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

Srivastava IK, Ulmer JB, Barnett SW.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. Review.

PMID:
15285704
16.

Toward an antibody-based HIV-1 vaccine.

Hoxie JA.

Annu Rev Med. 2010;61:135-52. doi: 10.1146/annurev.med.60.042507.164323. Review.

PMID:
19824826
17.

An effective HIV vaccine: A combination of humoral and cellular immunity?

Benmira S, Bhattacharya V, Schmid ML.

Curr HIV Res. 2010 Sep;8(6):441-9. Review.

PMID:
20636279
18.

RV144: old vs. new.

Weiner DB.

Hum Vaccin. 2010 Feb;6(2):159-61. Epub 2010 Feb 18. No abstract available.

PMID:
20431335
19.

Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection.

DeVico A.

Curr HIV Res. 2013 Jul;11(5):343-4. No abstract available.

PMID:
24191941
20.

Prospects for vaccine protection against HIV-1 infection and AIDS.

Letvin NL, Barouch DH, Montefiori DC.

Annu Rev Immunol. 2002;20:73-99. Epub 2001 Oct 4. Review.

PMID:
11861598

Supplemental Content

Support Center